FrancophonIA/ELRC3.0 huggingface dataset:
English: - increase in cholesterol and triglycerides (fats in your blood that would be detected during blood tests) - limb or skin swelling - problems with your eyes, such as difficulty seeing out of one or both eyes, double vision, or perceived flashes of light - problems with the nerves in your arms and legs, such as pain, numbness, unusual sensations like burning or pins and needles, difficulty walking, or difficulty with usual activities of daily living such as writing - increased level of enzymes called lipase and/or amylase in the blood that would be detected during blood tests - low number of red blood cells known as anaemia that would be detected during blood tests - diarrhoea - constipation - pain in your joints - weight gain - headache - rash - muscle pain
Danish: Meget almindelige (kan forekomme hos mere end 1 ud af 10 personer) - stigning i indholdet af kolesterol og triglycerider (fedt i dit blod, det vil kunne ses i blodprøver) - hævelse af lemmer eller hud - problemer med dine øjne, såsom besvær med at se med et eller begge øjne, dobbeltsyn eller opfattelse af lysglimt - problemer med nerverne i arme og ben, såsom smerter, følelsesløshed, usædvanlig sviende fornemmelse eller prikken, gangvanskeligheder eller svært ved at udføre sædvanlige dagligdags aktiviteter såsom at skrive - forøgelse af enzymerne lipase og/eller amylase i blodet, det vil kunne ses i blodprøver - lavt antal røde blodceller (anæmi), det vil kunne ses i blodprøver - diarré - forstoppelse - smerter i leddene - vægtøgning - hovedpine - udslæt - muskelsmerter
English: Recommended lorlatinib dose modifications for adverse reactions Adverse reactiona
Danish: Anbefalede dosisjusteringer af lorlatinib ved bivirkninger Bivirkning
English: Two or more prior ALK TKIs with or without prior chemotherapy
Danish: To eller flere forudgående ALK TKI'er med eller uden forudgående kemoterapi (N = 48)
English: Introduce the use of lipid-lowering therapy;b if currently on lipid-lowering therapy, increase the dose of this therapyb in accordance with respective prescribing information; or change to a new lipid-lowering therapyb.
Danish: Introducér anvendelsen af lipidsænkende behandling b; hvis patienten i øjeblikket får lipidsænkende terapi, øg dosis af denne behandling b i henhold til den respektive doseringsanvisning, eller skift til en ny lipidsænkende behandling b. Fortsæt lorlatinib ved samme dosis uden afbrydelse.
English: Few data are available over the 10 to 200 mg dose range; however, no deviation from linearity was observed for AUCinf and Cmax after single dose.
Danish: Ved en enkelt dosis steg lorlatinibs systemiske eksponering (AUCinf og Cmax) på en dosisrelateret måde i dosisintervallet 10 til 200 mg. Der er kun få data tilgængelige i dosisintervallet 10 til 200 mg; men der blev ikke observeret nogen afvigelse fra lineariteten for AUCinf og Cmax efter en enkelt dosis.
English: - efavirenz, cobicistat, ritonavir, paritaprevir in combination with ritonavir and ombitasvir and/or dasabuvir, and ritonavir in combination with either elvitegravir, indinavir, lopinavir or tipranavir - medicines used to treat AIDS/HIV.
Danish: - efavirenz, cobicistat, ritonavir, paritaprevir i kombination med ritonavir og ombitasvir og/eller dasabuvir, og ritonavir i kombination med enten elvitegravir, indinavir, lopinavir eller tipranavir,
English: Round (8 mm) light pink immediate release film-coated tablet, debossed with “Pfizer” on one side and “25” and “LLN” on the other side.
Danish: Runde (8 mm) svagt lyserøde filmovertrukne tabletter med øjeblikkelig frigivelse med ”Pfizer” præget på den ene side og ”25” og ”LLN” på den anden side.
English: INFORMATION IN BRAILLE Lorviqua 100 mg
Danish: Lorviqua 100 mg
English: How to store Lorviqua 6.
Danish: Sådan skal du tage Lorviqua 4.
English: Concomitant administration of lorlatinib with strong CYP3A4/5 inducers (e.g. rifampicin, carbamazepine, enzalutamide, mitotane, phenytoin and St. John's wort) may decrease lorlatinib plasma concentrations.
Danish: Samtidig administration af lorlatinib med stærke CYP3A4/5-inducere (f.eks. rifampicin, carbamazepin, enzalutamid, mitotan, phenytoin og prikbladet perikum) kan reducere lorlatinibs plasmakoncentration.
English: Your doctor may decide to reduce your dose of Lorviqua or stop your treatment.
Danish: Din læge kan beslutte sig for at nedsætte dosis af Lorviqua eller standse behandlingen.
English: No dose adjustments are recommended for patients with mild hepatic impairment.
Danish: Der anbefales ingen dosisjustering for patienter med let nedsat leverfunktion.
English: Oval (8.5 × 17 mm) dark pink immediate release film-coated tablet, debossed with “Pfizer” on one side and “LLN 100” on the other side.
Danish: Ovale (8,5 x 17 mm) mørkt lyserøde filmovertrukne tabletter med øjeblikkelig frigivelse med ”Pfizer” præget på den ene side og ”LLN 100” på den anden side.
English: CYP3A4/5 inhibitors
Danish: CYP3A4/5-substrater
English: Then resume lorlatinib at 1 reduced dose level.
Danish: Fortsæt derefter lorlatinib ved 1 reduceret dosisniveau.
English: Lorviqua 100 mg: each film-coated tablet (tablet) contains 100 mg lorlatinib.
Danish: Lorviqua 100 mg: hver filmovertrukket tablet (tablet) indeholder 100 mg lorlatinib.
English: Thus, concurrent administration of lorlatinib with CYP3A4/5 substrates with narrow therapeutic indices, including but not limited to alfentanil, ciclosporin, dihydroergotamine, ergotamine, fentanyl, hormonal contraceptives, pimozide, quinidine, sirolimus and tacrolimus, should be avoided since the concentration of these medicinal products may be reduced by lorlatinib (see section 4.4).
Danish: Derfor skal samtidig administration af lorlatinib med CYP3A4/5-substrater med snævert terapeutisk indeks, herunder, men ikke begrænset til, alfentanil, ciclosporin, dihydroergotamin, ergotamin, fentanyl, hormonel kontraception, pimozid, quinidin, sirolimus og tacrolimus, undgås, da koncentrationen af disse lægemidler kan reduceres af lorlatinib (se pkt.
English: Left ventricular ejection fraction decrease
Danish: Fald i venstre ventrikels uddrivningsfraktion
English: Concurrent administration of lorlatinib with CYP3A4/5 substrates with narrow therapeutic indices, including but not limited to alfentanil, ciclosporin, dihydroergotamine, ergotamine, fentanyl, hormonal contraceptives, pimozide, quinidine, sirolimus and tacrolimus, should be avoided since the concentration of these medicinal products may be reduced by lorlatinib (see section 4.5).
Danish: Samtidig administration af lorlatinib med CYP3A4/5-substrater med snævert terapeutisk indeks, herunder, men ikke begrænset til, alfentanil, ciclosporin, dihydroergotamin, ergotamin, fentanyl, hormonel kontraception, pimozid, quinidin, sirolimus og tacrolimus, skal undgås, da koncentrationen af disse lægemidler kan reduceres af lorlatinib (se pkt.
English: Mild hypertriglyceridaemia (triglycerides between 150 and 300 mg/dL or 1.71 and 3.42 mmol/L)
Danish: Let hypertriglyceridæmi (triglycerider mellem 150 og 300 mg/dl eller 1,71 og 3,42 mmol/l)
English: i
Danish: a
English: Concomitant use of strong CYP3A4/5 inducers (see sections 4.4 and 4.5).
Danish: Samtidig anvendelse af stærke CYP3A4/5-inducere (se pkt.
English: The use of a strong CYP3A4/5 inducer with lorlatinib is contraindicated (see sections 4.3 and 4.4).
Danish: Anvendelsen af en stærk CYP3A4/5-inducer sammen med lorlatinib er kontraindiceret (se pkt.
English: INFORMATION IN BRAILLE Lorviqua 25 mg
Danish: Lorviqua 25 mg
English: Moderate hypertriglyceridaemia (triglycerides between 301 and 500 mg/dL or 3.43 and 5.7 mmol/L)
Danish: Moderat hypertriglyceridæmi (triglycerider mellem 301 og 500 mg/dl eller 3,43 og 5,7 mmol/l)
English: Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines, including herbal medicines and medicines obtained over the counter.
Danish: Fortæl det altid til lægen, apotekspersonalet eller sygeplejersken, hvis du tager anden medicin eller har gjort det for nylig.
English: Pfizer Kft. Tel.: +36-1-488-37-00
Danish: Tel.: +36-1-488-37-00
English: General disorders and administration site conditions Oedemal Fatiguem
Danish: Almene symptomer og reaktioner på administrationsstedet Ødem Træthed
English: Eye disorders Vision disorderh
Danish: Øjne Synsforstyrrelser
English: - Contraception - information for women You should not become pregnant while taking this medicine.
Danish: Du må ikke blive gravid, mens du tager denne medicin.
English: Severe hypertriglyceridaemia (triglycerides between 501 and 1,000 mg/dL or 5.71 and 11.4 mmol/L)
Danish: Alvorlig hypertriglyceridæmi (triglycerider mellem 501 og 1.000 mg/dl eller 5,71 og 11,4 mmol/l)
English: What Lorviqua looks like and contents of the pack Lorviqua 25 mg is supplied as round light pink film-coated tablets, debossed with “Pfizer” on one side and “25” and “LLN” on the other side.
Danish: Lorviqua 25 mg leveres som runde, svagt lyserøde filmovertrukne tabletter med ”Pfizer” præget på den ene side og ”25” og ”LLN” på den anden side.
English: Lorlatinib may have the potential to inhibit CYP2C9.
Danish: In vitro-studier af anden CYP-hæmning og -induktion Lorlatinib kan muligvis hæmme CYP2C9.
English: Your doctor may investigate further and may decide to reduce your dose of Lorviqua or stop your treatment.
Danish: Din læge kan undersøge det yderligere og kan beslutte sig for at nedsætte dosen af Lorviqua eller standse behandlingen.
English: How to take Lorviqua
Danish: Sådan skal du tage Lorviqua
English: Each film-coated tablet contains 1.58 mg of lactose monohydrate.
Danish: Hjælpestof, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 1,58 mg lactosemonohydrat.
English: Concomitant use of a strong CYP3A4/5 inducer is contraindicated (see sections 4.3 and 4.5).
Danish: Samtidig anvendelse af en stærk CYP3A4/5-inducer er kontraindiceret (se pkt.
English: How Lorviqua works
Danish: Sådan virker Lorviqua
English: depression, euphoric mood, irritability, mania, mood altered, mood swings, personality change, stress).
Danish: Virkninger på humøret (herunder affektiv lidelse, affektlabilitet, aggression, agitation, angst, nedtrykthed, depression, eufori, irritabilitet, mani, ændret humør, humørsvingninger, personlighedsændring, stress).
English: Hypercholesterolaemia/hypertriglyceridaemia
Danish: Hyperkolesterolæmi/hypertriglyceridæmi
English: Medicinal products whose plasma concentrations may be altered by lorlatinib CYP3A4/5 substrates
Danish: Lægemidler, hvis plasmakoncentrationer kan ændres af lorlatinib
English: Oedema (including generalised oedema, oedema, oedema peripheral, peripheral swelling, swelling).
Danish: Ødem (herunder generaliseret ødem, ødem, perifert ødem, perifer hævelse, hævelse).
English: One prior ALK TKIa with or without prior chemotherapy
Danish: En forudgående ALK TKIa med eller uden forudgående kemoterapi (N = 9)
English: Lorviqua 100 mg film-coated tablets
Danish: Lorviqua 100 mg filmovertrukne tabletter
English: Lorviqua 25 mg film-coated tablets
Danish: Lorviqua 25 mg filmovertrukne tabletter
English: Each film-coated tablet contains 4.20 mg of lactose monohydrate.
Danish: Hjælpestof, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 4,20 mg lactosemonohydrat.
English: Lorviqua 25 mg film-coated tablets Lorviqua 100 mg film-coated tablets
Danish: Lorviqua 25 mg filmovertrukne tabletter Lorviqua 100 mg filmovertrukne tabletter
English: NAME OF THE MEDICINAL PRODUCT Lorviqua 100 mg tablets lorlatinib
Danish: Lorviqua 100 mg tabletter lorlatinib
English: NAME OF THE MEDICINAL PRODUCT Lorviqua 25 mg tablets lorlatinib
Danish: Lorviqua 25 mg tabletter lorlatinib
English: Lorviqua 25 mg film-coated tablets Lorviqua 100 mg film-coated tablets lorlatinib
Danish: Lorviqua 25 mg filmovertrukne tabletter Lorviqua 100 mg filmovertrukne tabletter lorlatinib
English: Interstitial lung disease (ILD)/Pneumonitis Grade 1: Mild
Danish: Interstitiel lungesygdom (ILS)/pneumonitis
English: MARKETING AUTHORISATION NUMBER(S) EU/1/19/1355/002
Danish: EU/1/19/1355/002
English: Pneumonitisi
Danish: Tabletkerne
English: Introduce the use of lipid-lowering therapyb or increase the dose of this therapyb in accordance with respective prescribing information or change to a new lipid-lowering therapyb.
Danish: Introducér anvendelsen af lipidsænkende behandling eller øg dosis af denne behandling b i henhold til den respektive doseringsanvisning, eller skift til en ny lipidsænkende behandling b. Tilbagehold lorlatinib indtil der ses forbedring af hyperkolesterolæmi og/eller hypertriglyceridæmi til moderat eller let alvorlighedsgrad.
English: Constipation
Danish: Forstoppelse
English: A highly effective non-hormonal method of contraception is required for female patients during treatment with lorlatinib, because lorlatinib can render hormonal contraceptives ineffective (see sections 4.4 and 4.5).
Danish: En meget effektiv, ikkehormonel kontraceptionsmetode er påkrævet til kvinder under behandling med lorlatinib.
English: Hypersensitivity to lorlatinib or to any of the excipients listed in section 6.1.
Danish: Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne anført i pkt.
English: NAME OF THE MEDICINAL PRODUCT Lorviqua 100 mg film-coated tablets lorlatinib
Danish: Lorviqua 100 mg filmovertrukne tabletter lorlatinib
English: Hypromellose
Danish: Natrium
English: NAME OF THE MEDICINAL PRODUCT Lorviqua 25 mg film-coated tablets lorlatinib
Danish: Lorviqua 25 mg filmovertrukne tabletter lorlatinib
English: Dose modifications
Danish: Dosisjusteringer
English: Magyarország
Danish: Danmark
English: Microcrystalline cellulose
Danish: Hypromellose Lactosemonohydrat Macrogol
English: Pneumonitis (including interstitial lung disease, pneumonitis).
Danish: Pneumonitis (herunder interstitiel lungesygdom, pneumonitis) Udslæt (herunder akneiform dermatitis, makulopapuløst udslæt, pruritisk udslæt, udslæt) Myalgi (herunder muskuloskeletale smerter, myalgi)
English: Musculoskeletal and connective tissue disorders Arthralgia Myalgiak
Danish: Knogler, led, muskler og bindevæv Artralgi
English: The European Commission granted a marketing authorisation valid throughout the European Union for Angiox on 20 September 2004.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Angiox den 20. september 2004.
English: The full EPAR for Angiox can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Angiox findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Angiox.
Danish: Dette er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Angiox.
English: The studies also looked at the number of patients who had major bleeding.
Danish: I undersøgelserne så man desuden nærmere på antallet af patienter med større blødninger.
English: Other information about Angiox
Danish: Andre oplysninger om Angiox
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Angiox.
Danish: Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Angiox.
English: In all three studies, the patients also received other medicines to prevent blood clots, such as aspirin and clopidogrel.
Danish: I alle tre undersøgelser fik patienterne også andre lægemidler til forebyggelse af blodpropper, såsom aspirin og clopidogrel.
English: The dose of Angiox and the duration of treatment depend on why it is being used.
Danish: Dosis af Angiox og behandlingens varighed afhænger af årsagen til lægemidlets anvendelse.
English: The most common side effect with Angiox (seen in more than 1 patient in 10) is minor bleeding.
Danish: Den hyppigste bivirkning ved Angiox (som optræder hos flere end 1 ud af 10 patienter) er mindre blødninger.
English: Using Angiox greatly reduces the risk of a blood clot forming.
Danish: Anvendelse af Angiox nedsætter i høj grad risikoen for dannelse af blodpropper.
English: Angiox is a medicine that contains the active substance bivalirudin.
Danish: Angiox er et lægemiddel, der indeholder det aktive stof bivalirudin.
English: The first dose is given by injection into a vein, which must be followed immediately by an infusion for at least the duration of the procedure.
Danish: Den første dosis indgives ved injektion i en vene, som omgående skal efterfølges af en infusion, der som minimum skal vare lige så længe som indgrebet.
English: It decided that Angiox's benefits are greater than its risks and recommended that it be given marketing authorisation.
Danish: Udvalget besluttede, at fordelene ved Angiox opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
English: Angiox is used together with aspirin and clopidogrel (other medicines that help to prevent blood clots).
Danish: Angiox anvendes sammen med aspirin og clopidogrel (andre lægemidler, der hjælper med at forebygge blodpropper).
English: For more information about treatment with Angiox, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Angiox, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: It must also not be used in patients who have recently been bleeding, or who have severe high blood pressure, severe kidney problems or a heart infection.
Danish: Det må heller ikke anvendes af patienter, der for nyligt har haft blødninger, eller patienter med stærkt forhøjet blodtryk, med alvorlige nyresygdomme eller med en hjerteinfektion.
English: Blood clotting can be a problem when blood clots develop inside blood vessels and restrict the blood flow to major organs such as the heart and the brain.
Danish: Blodkoagulation kan være et problem, når der opstår blodpropper i blodkarrene, som begrænser blodtilstrømningen til vigtige organer som f.eks. hjertet og hjernen.
English: The rate of the infusion needs to be reduced in patients with moderate kidney problems who are undergoing PCI.
Danish: Infusionshastigheden skal nedsættes hos patienter med moderate nyresygdomme, som får foretaget PCI.
English: It was most effective in patients who also took aspirin and clopidogrel.
Danish: Angiox var mest effektivt hos patienter, der også fik aspirin og clopidogrel.
English: Almost 4,000 of the patients were having PCI to treat myocardial infarction with ST segment elevation.
Danish: Næsten 4 000 af patienterne fik foretaget PCI til behandling af myokardieinfarkt med forhøjelse af ST-segmentet.
English: The main measure of effectiveness was the reduction in the number of patients who had an ‘ischaemic event' (a problem caused by reduced blood flow) including death, a heart attack, urgent revascularisation (restoration of blood flow to the heart) or stroke after 30 days.
Danish: Virkningen blev hovedsageligt bedømt på reduktionen af antallet af patienter, der oplevede "iskæmiske tilfælde" (et problem forårsaget af reduceret blodtilførsel), herunder antallet af dødsfald, hjertetilfælde, akut revaskularisering (genoprettelse af blodtilstrømningen til hjertet) eller slagtilfælde efter 30 dage.
English: This can improve the effectiveness of PCI and help to maintain the flow of blood to the heart in patients with angina or myocardial infarction.
Danish: Dette kan gøre PCI mere effektiv og bidrage til at opretholde blodtilstrømningen til hjertet hos patienter med angina eller myokardieinfarkt.
English: In PCI, Angiox has been compared withanother type of anticoagulant, a heparin, in two studies involving a total of almost 10,000 adults.
Danish: Ved PCI blev Angiox sammenlignet med en anden type antikoagulerende middel, heparin, i to undersøgelser, der i alt omfattede omkring 10 000 voksne.
English: What measures are being taken to ensure the safe use of Angiox?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri anvendelse af Angiox?
English: The CHMP concluded that Angiox is an acceptable substitute for heparin during PCI and in the treatment of unstable angina and myocardial infarction.
Danish: CHMP konkluderede, at Angiox er en acceptabel erstatning for heparin ved PCI og under behandlingen af ustabil angina og myokardieinfarkt.
English: This includes patients who are having myocardial infarction (a heart attack) with ‘ST segment elevation' (an abnormal reading on the electrocardiogram or ECG).
Danish: Dette omfatter patienter, som har myokardieinfarkt (et hjertetilfælde) med "forhøjelse af ST-segmentet" (en unormal visning på elektrokardiogrammet (EKG)).
English: Angiox should be given by a doctor who has experience in the emergency care of patients with heart problems or in carrying out procedures on the heart.
Danish: Angiox skal administreres af en læge, der har erfaring med akut behandling af patienter med hjerteproblemer eller med udførelse af hjerteindgreb.
English: The active substance in Angiox, bivalirudin, is a synthetic substance originally derived from hirudin, the anticoagulant substance produced by leeches.
Danish: Det aktive stof i Angiox, bivalirudin, er et syntetisk stof, der oprindeligt fremstilles på basis af hirudin, som er det antikoagulerende stof, der produceres af igler.
English: It is available as a powder that is made up into a solution for injection or infusion (drip) into a vein.
Danish: Det fås som et pulver, der blandes til en opløsning til injektion eller infusion (drop i en vene).
English: For the full list of all side effects reported with Angiox, see the package leaflet.
Danish: Den fuldstændige liste over alle indberettede bivirkninger ved Angiox fremgår af indlægssedlen.
English: Thrombin is central to the processes involved in blood clotting.
Danish: Trombin spiller en central rolle i blodkoagulationsprocesserne.
English: It specifically blocks one of the substances involved in the clotting process called thrombin.
Danish: Det blokerer specielt ét af de stoffer, der medvirker ved blodets koagulering, nemlig trombin.
English: Angiox is an anticoagulant, which means that it prevents the blood from clotting.
Danish: Angiox er et antikoagulerende middel, dvs. det forhindrer blodet i at koagulere.
English: Heparin was given in combination with a glycoprotein IIb/IIIa inhibitor (GPI, another type of medicine that helps to prevent blood clots) and some patients receiving Angiox were also given a GPI where appropriate.
Danish: Heparin blev indgivet i kombination med en glykoprotein IIb/IIIa-hæmmer (GPI, en anden type lægemiddel, der hjælper med at forebygge blodpropper), og enkelte patienter, der blev behandlet med Angiox, fik ligeledes en GPI i de tilfælde, hvor det var hensigtsmæssigt.
English: Angiox must not be used in people whoare hypersensitive (allergic) to bivalirudin, other hirudins, or any of the other ingredients.
Danish: Angiox må ikke anvendes af patienter, der er overfølsomme (allergiske) over for bivalirudin, andre hirudiner eller andre af indholdsstofferne.
English: In both studies of patients undergoing PCI, Angiox (alone or with a GPI where appropriate) was as effective as heparin in combination with a GPI at preventing new ischaemic events.
Danish: I begge undersøgelser af patienter, der fik foretaget PCI, var Angiox (alene eller med en GPI i de tilfælde, hvor det var hensigtsmæssigt) lige så effektivt som heparin i kombination med en GPI til forebyggelse af nye iskæmiske tilfælde.
English: In patients being treated for angina or myocardial infarction without ST segment elevation, the duration of the infusion depends on how the patient is going to be treated.
Danish: Hos patienter, der behandles for angina eller myokardieinfarkt uden forhøjelse af ST-segmentet, afhænger infusionens varighed af, hvordan patienten skal behandles.
English: Why has Angiox been approved?
Danish: Hvorfor blev Angiox godkendt?